1031.9000 -2.60 (-0.25%)
NSE Sep 17, 2025 09:54 AM
Volume: 82,051
 

1031.90
-0.25%
Sharekhan
Cadila Healthcare Limited (Cadila) reported 22.2% y-o-y growth in total operating revenue to Rs. 3,496.3 crore (2% above estimate). Operating profit (adjusted for one-time cost of Rs. 70 related to acquisition) reported 14.8% y-o-y growth to Rs. 702 crore (6.5% above estimate); OPM declined by 130 BPS y-o-y to 20.1% (100 BPS above our estimate of 19.1%). Adjusted profit grew by 14.5% to Rs. 384.8 crore (11.9 % above estimates). Strong sales growth was mainly due to consumer wellness business in India (acquisition led). India human formulation reported 6%...
Geojit BNP Paribas increased Buy price target of Zydus Lifesciences Ltd. to 1121.0 on 03 Sep, 2025.
More from Zydus Lifesciences Ltd.
Recommended